The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis

BACKGROUND: Respiratory tract infections (RTIs) and interstitial lung disease (ILD) secondary to interleukin (IL) 12/23 or IL-23 antagonists have been reported in autoimmune diseases. OBJECTIVE: To assess the risk of RTIs and noninfectious ILD with these drugs. METHODS: We conducted a systematic rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Akiyama, Shintaro, Yamada, Akihiro, Micic, Dejan, Sakuraba, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American Academy of Dermatology, Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417275/
https://www.ncbi.nlm.nih.gov/pubmed/32791083
http://dx.doi.org/10.1016/j.jaad.2020.08.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417275/
https://www.ncbi.nlm.nih.gov/pubmed/32791083
http://dx.doi.org/10.1016/j.jaad.2020.08.026

Ejemplares similares